00:30 , May 31, 2014 |  BC Extra  |  Financial News

Dara to raise $12.5 million in public offering

Dara BioSciences Inc. (NASDAQ: DARA) plans to raise about $12.5 million through the sale of 12,500 units at $1,000 in a public offering. The units comprise: convertible preferred series C-1 shares; a five-year warrant to...
08:00 , Nov 4, 2013 |  BC Week In Review  |  Company News

Dara BioSciences, Mission Pharmacal sales and marketing update

Mission granted Dara exclusive commercialization rights in the U.S. to three marketed drugs - Ferralet for anemia, Binosto alendronate for osteoporosis and Aquoral for xerostomia. Additionally, Dara entered a deal with Mission's Alamo...
07:00 , Sep 24, 2012 |  BC Week In Review  |  Company News

Innocutis sales and marketing update

Innocutis launched three new formulations of Bionect 0.2% hyaluronic acid in the U.S. to treat skin irritation and burns: 20 mL Bionect Spray; 100 g Bionect Cream; and 100 g Bionect Gel. Dara...
07:00 , Jun 11, 2012 |  BC Week In Review  |  Company News

Dara BioSciences sales and marketing update

Dara launched Bionect 0.2% hyaluronic acid in the U.S. to treat skin irritation and burns associated with radiation therapy. Dara has exclusive, U.S. commercialization rights to Bionect for cancer and radiation cancer indications from...
07:00 , Apr 2, 2012 |  BC Week In Review  |  Company News

Dara BioSciences, Innocutis sales and marketing update

Innocutis granted Dara exclusive, U.S. commercialization rights to Bionect 0.2% hyaluronic acid for cancer and radiation cancer indications. The low molecular weight formulation of hyaluronic acid is approved by FDA to treat skin irritation...